logo
logo

Evommune Inc., Completes $83 Million Series A Financing To Advance Development Of Unique Chronic Inflammation Pipeline

Sep 09, 2021•about 4 years ago

Amount Raised

$83 Million

Round Type

series a

Los Altos

Description

Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced the completion of an $83 million Series A financing which included Andera Partners and LSP, who joined forces with a global syndicate of investors and existing investor, Pivotal bioVenture Partners. The financing enables Evommune to continue the research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases.

Company Information

Company

Evommune

Location

Los Altos, California, United States

About

Evommune is a private R&D company and innovation engine in chronic inflammation. The company is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases. The company is headquartered in Los Altos, Calif. For more information, please visit Evommune.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech